Quinta-Analytica

Executive Summary

Quinta-Analytica is a well-established, GxP-certified contract research organization (CRO) based in Prague, Czech Republic, operating since 1991. The company specializes in analytical development, quality control, bioanalysis (GLP/GCP), and clinical study support (BE/BA/PK), with additional capabilities in GMP batch release, stability testing (including high-potency APIs), and biologics/biosimilar assays. Its comprehensive service portfolio and regulatory compliance position it as a reliable partner for pharmaceutical companies seeking outsourced analytical and bioanalytical services. Although serving the pharmaceutical industry, Quinta-Analytica itself is pre-clinical stage as a company, reflecting its role as a service provider rather than a drug developer. The company is privately held and has not disclosed funding or valuation, indicating a stable, self-sustaining business model. Its long track record and niche expertise in Central European CRO market suggest moderate growth potential driven by increasing outsourcing trends and demand for specialized analytical services.

Upcoming Catalysts (preview)

• Q2 2026Expansion of high-potency API (HAPI) stability testing capacity80% success
• Q4 2026New partnership or framework agreement with a major pharma for biosimilar bioanalysis60% success
• TBDRegulatory inspection (e.g., US FDA or EMA) with positive outcome, reinforcing GxP compliance70% success